Clinical trial
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With…
NCT00348309 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00348309 |
|---|---|
| Title | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease |
| Official title | A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. |
| Acronym | REFLECT-2 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug, Other |
| Interventions | Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil |
| Enrollment | 1,496 |
| Start date | Jul 6, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 28, 2009 |
| First posted | Jul 4, 2006 |
| Last update posted | Nov 28, 2017 |
| Countries | Argentina, Austria, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Italy and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: